Investigation of five polymorphic DNA markers associated with late onset Alzheimer disease

Genetika

Volumn 45, Issue 2, 2013, Pages 503-514

  Gharesouran, Jalal ^a   Rezazadeh, Maryam ^a,b   Mojtaba Mohaddes Ardebili, Seiied ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

Author keywords

Alzheimer disease; CALHM1; CCR2; CCR5; Eastern Azerbaijan; TNF

Indexed keywords

EID: 84891503353     PISSN: 05340012     EISSN: 18206069     Source Type: Journal    
DOI: 10.2298/GENSR1302503G     Document Type: Article

References (36)

1. AQDAM, M.J, K KAMALI, M RAHGOZAR, M OHADI, M MANOOCHEHRI, A TAHAMI, L BOSTANSHIRIN, HR KHORRAMKHORSHID (2010): Association of CALHM1 Gene Polymorphism with Late Onset Alzheimer's Disease in Iranian Population. AJMB. 2: 153-157.
2. AKIYAMA, H, S BARGER, S BARNUM, B BRADT, J BAUER, GM COLE, NR COOPER, P EIKELENBOOM, M EMMERLING, B.L FIEBICH, CE FINCH, S FRAUTSCHY, WS GRIFFIN, H HAMPEL M, HULL, G LANDRETH,, L LUE, R MRAK, IR MACKENZIE, PL MCGEER, MK O'BANION, J PACHTER, G PASINETTI, C PLATA-SALAMAN, J ROGERS, R RYDEL, Y SHEN, W STREIT, R STROHMEYER, I TOOYOMA, FL VAN MUISWINKEL, R VEERHUIS, D WALKER, S WEBSTER, B WEGRZYNIAK, G WENK, T WYSS-CORAY (2000): Inflammation and Alzheimer's disease. Neurobiol Aging. 21(3): 383-421.
3. BAJETTO, A, R BONAVIA, S BARBERO, G SCHETTINI (2002: Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem. 82(6): 1311-1329.
4. BALES, KR, Y DU, D HOLTZMAN, B CORDELL, SM PAUL (2000): Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging. 21(3): 427-32.
5. BERTRAM, L, BM SCHJEIDE, B HOOLI, K MULLIN, M HILTUNEN, H SOININEN, M INGELSSON, L LANNFELT, D BLACKER, RE TANZI (2008: No Association between CALHM1 and Alzheimer's disease risk. Cell. 135: 993-996.
6. BOADA, M, C ANTÚNEZ, J LÓPEZ -ARRIETA, JJ GALÁN, FJ MORÓN, I HERNÁNDEZ, J MARÍN, MARTÍNEZ- P LAGE, M ALEGRET, JM CARRASCO, C MORENO, LM REAL, A GONZÁLEZ-PÉREZ, L TÁRRAGA, A RUIZ (2010): CALHM1 P86L polymorphism is associated with late-onset Alzheimer's disease in a recessive model. J Alzheimer's Dis., 20: 247-251.
7. BONOTIS, K, E KRIKKI, V HOLEVA, C AGGOURIDAKI, V COSTA, S BALOYANNIS (2008): Systemic immune aberrations in Alzheimer's disease patients. J. Neuroimmunol. 193, 183-187.
8. CUI, PJ, L ZHENG, L CAO, Y WANG, YL DENG, G WANG, W XU, HD TANG, JF MA, T ZHANG, JQ DING, Q CHENG, SD CHEN (2010): CALHM1 P86L polymorphism is a risk factor for Alzheimer's disease in the Chinese population. J Alzheimer's Dis. 19: 31-35.
9. DEAN, M, M CARRINGTON, SJ O'BRIEN (2002): Balanced polymorphism selected by genetic versus infectious human disease. Annu. Rev. Genomics Hum. Genet. 3: 263-292.
10. DI BD, G CANDORE, C FRANCESCHI, F LICASTRO, G COLONNA-ROMANO, C CAMMA, et al. (2009) Systematic review by metaanalyses on the possible role of TNF-αlpha polymorphisms in association with Alzheimer's disease. Brain Res Rev. 61(2): 60-8.
11. DRESES-WERRINGLOER, U, JC LAMBERT, V VINGTDEUX, H ZHAO, H VAIS, A SIEBERT, A JAIN, J KOPPEL,, A ROVELETLECRUX, D HANNEQUIN, F PASQUIER, D GALIMBERTI, E SCARPINI, D MANN, C LENDON, D CAMPION, P AMOUYEL, P DAVIES, JK FOSKETT, F CAMPAGNE, P MARAMBAUD (2008): A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 133(7): 1149-61.
12. FARGION, S, L VALENTI, P DONGIOVANNI, AL FRACANZANI (2004): TNFalpha promoter polymorphisms. Methods Mol Med. 98: 47-58.
13. FAVOROVA, OO, TV ANDREEWSKI, AN BOIKO, MA SUDOMOINA, AD ALEKSEENKOV, OG KULAKOVA, et al. (2002): The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology. 59:1652-5.
14. FELDMANN, M, RN MAINI (2003) :Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 9(10): 1245-50.
15. GALIMBERTI, D, C FENOGLIO, C LOVATI, A GATTI, I GUIDI, E VENTURELLI, GR CUTTER, C MARIANI, G FORLONI, C PETTENATI, P BARON, G CONTI, N BRESOLIN, E SCARPINI (2004: CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. J Neurol Sci. 15;225(1-2):79-83.
16. HARRIES, LW, RM BRADLEY-SMITH, DJ LLEWELLYN, LC PILLING, A FELLOWS, W HENLEY, D HERNANDEZ, JM GURALNIK, S BANDINELLI, A SINGLETON, L FERRUCCI, D MELZER (2012): Leukocyte CCR2 Expression Is Associated with Mini-Mental State Examination Score in Older Adults. Rejuvenation Res. 4:395-404. Epub.
17. HUERTA, C, V ALVAREZ, IF MATA, E COTO, R RIBACOBA, C MARTÍNEZ, M BLÁZQUEZ, LM GUISASOLA, C SALVADOR, CH LAHOZ, J PEÑA (2004): Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett. 370(2-3):151-4.
18. INOUE, K, N TANAKA, F YAMASHITA, Y SAWANO, T ASADA, Y GOTO (2010): The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts. Am J Med Genet B Neuropsychiatr Genet., 1532: 532-535.
19. JILLIAN, J (2009): Alzheimer disease: Alzheimer's disease neuropathology in the oldest old. Nat RevNeurol., 5: 411-412. KHACHATURIAN, ZS (1989): Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann. N.Y. Acad. Sci., 568: 1-4.
20. KHACHATURIAN, ZS (1989): Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann. N.Y. Acad. Sci., 568: 1-4.
21. KHORRAM KHORSHID, HR, M MANOOCHEHRI, L NASEHI, M OHADI, M RAHGOZAR, K KAMALI (2011): Ccr2-64i and Ccr5 δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 δ32 Polymorphisms in Alzheimer's disease). J Basic Med Sci., 15(4): 937-944.
22. MOHADDES, SM, M REZAZADEH, J GHARESOURAN, T YEGHANEH, M, ARHOUDI H AYROMLOU, M TALEBI, M GHOJAZADEH (2011) Association of CCR2 and CCR5 gene polymorphisms with Alzheimer's disease. JSCi. 22: 11-116.
23. ARDEBILI, SM, T YEGHANEH, J GHARESOURAN, M REZAZADEH, M FARHOUDI, H AYROMLOU, M TALEBI, M GHOJAZADEH (2011). Genetic association of TNF-α-308 G/A and -863 C/A polymorphisms with late onset Alzheimer's disease in Azeri Turk population of Iran. J Res Med Sci., 16(8):1006-13.
24. NACMIAS, B, A TEDDE, S BAGNOLI, E LUCENTEFORTE, E CELLINI, I PIACERI, BM GUARNIERI, V BESSI, L BRACCO, S SORBI (2010): Lack of implication for CALHM1 P86L common variation in Italian patients with early and late onset Alzheimer's disease. J Alzheimer's Dis., 20: 37-41.
25. NAERT, G, S RIVEST (2012): Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med. 18(1):297-313. doi: 10.2119/molmed.2011.00306.
26. OLGIATI, P, AM POLITIS, GN PAPADIMITRIOU, DD RONCHI, A SERRETTI (2011): Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways.
27. PASTOR, P, AM GOATE (2004): Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep., 6: 125-133.
28. PERRY, VH, JA NICOLL, C HOLMES (2010): Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
29. RUBIO-PEREZ, JM, JM MORILLAS-RUIZ (2012): A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World Journal 75,6357.
30. SESHADRI, S, AL FITZPATRICK, MA IKRAM, AL DESTEFANO, V GUDNASON, M BOADA, JC BIS, AV SMITH, MM CARASSQUILLO, JC LAMBERT, D HAROLD, EM SCHRIJVERS, R RAMIREZ-LORCA, S DEBETTE, WT LONGSTRETH, AC JANSSENS, VS PANKRATZ, JF DARTIGUES, P HOLLINGWORTH, T ASPELUND, I HERNANDEZ, A BEISER, LH KULLER, PJ KOUDSTAAL, DW DICKSON, C TZOURIO, R ABRAHAM, C ANTUNEZ, Y DU, JI ROTTER, YS AULCHENKO, TB HARRIS, RC PETERSEN, C BERR, MJ OWEN, J LOPEZ-ARRIETA, BN VARADARAJAN, JT BECKER, F RIVADENEIRA, MA NALLS, NR GRAFF-RADFORD, D CAMPION, S AUERBACH, K RICE, A HOFMAN, PV JONSSON, H SCHMIDT, M LATHROP, TH MOSLEY, R AU, BM PSATY, AG UITTERLINDEN, LA FARRER, T LUMLEY, A RUIZ, J WILLIAMS, P AMOUYEL, SG YOUNKIN, PA WOLF, LJ LAUNER, OL LOPEZ, CM VAN DUIJN, MM BRETELER (2010): Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA.,303: 1832-1840.
31. SHARMA, V, V. THAKUR, SN SINGH, R. GULERIA (2012): Tumor Necrosis Factor and Alzheimer's Disease: A Cause and Consequence Relationship. Bulletin of Clinical Psychopharmacology, 22(1):86-97.
32. SHOJI, M, R. KUWANO, T. ASADA, M. IMAGAWA,.HIGUCHI,.URAKAMI,.ARAI,.IHARA (2005): Japanese Study Group Genome-wide screening for Genes associated Alzheimer's disease; Advanced Brain Science Project. A proposal for diagnostic and clinical assessment criteria for Alzheimer's disease. RinshoShinkeigaku., 45: 128-137.
33. TEDDE, A, AL PUTIGNANO,.NACMIAS,.BAGNOLI,.CELLINI, S. SORBI (2008): Lack of association between TNF-alpha polymorphisms and Alzheimer's disease in an Italian cohort. Neurosci Lett. Dec 3;446(2-3):139-42.
34. TUPPO, EE, HR ARIAS (2005): The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol.,37: 289-305.
35. WANG, FS, WG HONG, Y CAO, MX LIU, L, JIN LP HU, et al. (2003: Population survey of CCR5 D32, CCR5 m303, CCR2b 64I, and SDF1 3VA allele frequencies in indigenous Chinese Healthy individuals, and in HIV-1 infected and HIV-1 uninfected individuals in HIV-1 risk groups. J Acquir Immune Defic Syndr 32:124-30.
36. WESTIN, K, P. BUCHHAVE, H. NIELSEN, L. MINTHON, S. JANCIAUSKIENE, O. HANSSON (2012): CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 7(1):e30525.